MedPage Today  Sep 11  Comment 
(MedPage Today) -- Prescription fish oil marketing expands after court ruling
FiercePharma  Sep 9  Comment 
It looks like the federal court ruling last month that Amarin had the "free speech" right to promote its fish oil product Vascepa for off-label use will become nettlesome to the FDA. A second drugmaker, Pacira, has now filed suit looking for a...
MedPage Today  Aug 13  Comment 
(MedPage Today) -- Court decision drastically curtails FDA authority over drug marketing
FierceBiotech  Aug 13  Comment 
FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss a court ruling that could change how pharma companies market drugs, a biotech CEO's nuanced relationship with Twitter, and how Kim Kardashian's Instagram drew the ire of the FDA.
TheStreet.com  Aug 10  Comment 
NEW YORK ( TheStreet) -- Amarin 2015 earnings estimate was increased to a loss of $0.57 from a loss of $0.54 per share at Oppenheimer. The firm raised its 2016 earnings estimate to a loss of $0.23 per share from a loss of $0.22 per share....
Forbes  Aug 7  Comment 
A Federal judge in New York today granted Amarin Pharma’s request for an injunction against the enforcement by the U.S. Food & Drug Administration of rules that would otherwise prohibit the communication to physicians of truthful information...
New York Times  Aug 7  Comment 
The decision clears the way for Amarin to promote patient use of its drug Vascepa in a way that the F.D.A. declined to approve.
Motley Fool  Aug 7  Comment 
Amarin wins a key court battle against the FDA, and investors bid the stock up on the positive news.
FiercePharma  Aug 7  Comment 
On Friday, Amarin won what was being called a First Amendment free speech victory for drugmakers. It got a federal court to say the FDA cannot bar Amarin from discussing off-label use of its fish-oil drug Vascepa for a wider group of patients than...
Wall Street Journal  Aug 7  Comment 



This is a test No its not

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki